Multidrug-resistant tuberculosis (MDR-TB) refers to the case when a clinical TB isolate is resistant to two of the most potent tuberculosis medications: isoniazid and rifampin. Globally, there are about half a million new cases of MDR-TB per year. Prof. Timothy Rodwell (UC San Diego, San Diego, CA, US) discusses the limitations of MDR-TB diagnosis and assessment as well as the new developments in next-generation sequencing in MDR-TB treatment.
‘Shedding Light on New MDR-TB Treatment Decisions with Next Generation Sequencing’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- Could you give us a brief overview of multi drug resistant tuberculosis (MDR-TB) and its global health burden? (00:22)
- What have been the limitations of molecular testing for the diagnosis of and assessment of drug-resistant mutations in tuberculosis ? (01:02)
- What have been the latest developments in next generation sequencing tests in MDR-TB? (03:20)
Disclosures: Timothy Rodwell serves as a consultant for FIND; he receives grant/research support from NIH, DoD; he is a major stock shareholder in Verus Diagnostics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022.
Share this Video
Related Videos In Bacterial Infections
Prosthetic joint infections – advances in diagnosis and treatment approaches: Robin Patel, ECCMID 2023
Prosthetic joint infections (PJI) are difficult to treat and require a multidisciplinary approach including surgical and therapeutic approaches to overcome infection. We were delighted to speak with Dr. Robin Patel (Mayo Clinic, Rochester, MN, USA) to learn more around the incidence, pathogenesis, and prognosis of PJI, the challenges in diagnosis and treatment of PJI and […]
Clostridioides difficile infection in paediatric patients: unmet needs and future challenges: Anne J. Gonzales-Luna, ECCMID 2023
Clostridioides difficile infection (CDI) is usually associated with older age; however, is becoming more prevalent in paediatric patients often in concurrence with comorbidities. There remains many unmet needs in the diagnosis and treatment of CDI in paediatric patients, with the mainstay of treatment being antibiotics. touchINFECTIOUS DISEASES spoke with Dr. Anne J. Gonzales-Luna (University of […]
Kayla Stover Hielscher, IDWeek 2022: Ceftriaxone as a treatment option for MSSA, ensuring optimum activity
Ceftriaxone is frequently used to treat methicillin-susceptible Staphylococcus aureus (MSSA). In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss advantages and limitations of the use of ceftriaxone for the treatment of MSSA, and the data that exists to support its use […]